Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Clin Cancer Res. 2008 Sep 15;14(18):5643-5. doi: 10.1158/1078-0432.CCR-08-1557.


Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.

Publication types

  • Comment
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / blood
  • Female
  • Humans
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Prognosis
  • Proteins / analysis
  • Receptors, Cell Surface / blood
  • Receptors, Urokinase Plasminogen Activator


  • Biomarkers, Tumor
  • Nbr1 protein, rat
  • PLAUR protein, human
  • Plaur protein, rat
  • Proteins
  • Receptors, Cell Surface
  • Receptors, Urokinase Plasminogen Activator